Jason Keyes
Net worth: 315 622 $ as of 2024-03-30
Profile
Jason A.
Keyes served as the Senior Director-Finance at Amylin Pharmaceuticals, Inc. from 2007 to 2013.
He then worked as the Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc. from 2016 to 2018.
Following that, he became the Chief Financial Officer at Equillium, Inc. in 2018, a position he held until 2024.
In 2020, he also served as an Independent Director at Sesen Bio, Inc. .
Mr. Keyes obtained his undergraduate and graduate degrees from Stanford University.
He also holds an MBA from the University of California, Los Angeles, and another MBA from UCLA Anderson School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EQUILLIUM, INC.
0.39% | 2024-01-01 | 136,633 ( 0.39% ) | 315 622 $ | 2024-03-30 |
Former positions of Jason Keyes
| Companies | Position | End |
|---|---|---|
| EQUILLIUM, INC. | Director of Finance/CFO | 2024-03-05 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 2023-03-06 |
| OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 2018-02-22 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Director of Finance/CFO | 2012-12-31 |
Training of Jason Keyes
| Stanford University | Graduate Degree |
| University of California, Los Angeles | Masters Business Admin |
| UCLA Anderson School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EQUILLIUM, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jason Keyes
